Table 2 Baseline characteristics of the lymphoma cohort

From: Identification of novel genetic mutations for the treatment prognostication of canine lymphoma

Gene

Covariate

PFS (N = 117, events = 41)

OS (N = 208, events = 74)

HR (95% CI)

P-value

HR (95% CI)

P-value

PIK3CD

Genotype (MT vs WT)

3.4 (1.4–8.5)

0.0094

0.9 (0.3–2.6)

0.84

Immunophenotypea

2.2 (1.1–4.3)

0.022

1.2 (0.7–2.0)

0.61

Stage (III–V vs I–II)

0.6 (0.3–1.3)

0.2

1.2 (0.8–2.0)

0.37

Disease statusb

1.1 (0.4–3.1)

0.8

2.0 (1.2–3.4)

0.0057

NOTCH2

Genotype (MT vs WT)

0.9 (0.5–1.7)

0.8

0.9 (0.6–1.5)

0.72

Immunophenotype

2.4 (1.2–4.6)

0.0094

1.1 (0.7–2.0)

0.63

Stage (III–V vs I–II)

0.64 (0.32–1.3)

0.22

1.3 (0.8–2.1)

0.35

Disease status

1.05 (0.39–2.83)

0.92

2.0 (1.2–3.4)

0.006

KMT2C

Genotype (MT vs WT)

0.9 (0.5–1.8)

0.84

0.8 (0.5–1.2)

0.23

Immunophenotype

2.5 (1.3–4.8)

0.0092

1.2 (0.7–2.0)

0.54

Stage (III–V vs I–II)

0.6 (0.3–1.3)

0.22

1.3 (0.8–2.1)

0.32

Disease status

1.1 (0.4–3.0)

0.88

2.1 (1.3–3.4)

0.0048

CREBBP

Genotype (MT vs WT)

2.1 (1.1–3.9)

0.026

1.5 (0.9–2.4)

0.15

Immunophenotype

2.3 (1.2–4.4)

0.015

1.1 (0.7–1.9)

0.65

Stage (III–V vs I–II)

0.6 (0.3–1.3)

0.19

1.3 (0.8–2.0)

0.34

Disease status

1.2 (0.4–3.2)

0.75

2.2 (1.3–3.6)

0.0033

FBXW7

Genotype (MT vs WT)

1.0 (0.4–2.5)

0.92

0.5 (0.2–1.2)

0.14

Immunophenotype

2.4 (1.2–4.6)

0.01

1.1 (0.6–1.8)

0.81

Stage (III–V vs I–II)

0.6 (0.3–1.3)

0.2

1.3 (0.8–2.0)

0.34

Disease status

1.1 (0.4–2.8)

0.91

2.1 (1.3–3.5)

0.004

TRAF3

Genotype (MT vs WT)

0.4 (0.1–1.0)

0.049

0.9 (0.5–1.6)

0.7

Immunophenotype

1.4 (0.7–3.1)

0.39

1.1 (0.6–2.0)

0.79

Stage (III–V vs I–II)

0.6 (0.3–1.2)

0.17

1.2 (0.8–2.0)

0.38

Disease status

0.8 (0.3–2.2)

0.62

2.0 (1.2–3.4)

0.0059

KMT2D

Genotype (MT vs WT)

1.0 (0.5–1.8)

0.91

0.8 (0.5–1.2)

0.27

Immunophenotype

2.4 (1.3–4.6)

0.0086

1.1 (0.7–1.9)

0.67

Stage (III–V vs I–II)

0.6 (0.3–1.3)

0.2

1.2 (0.7–1.9)

0.53

Disease status

1.1 (0.4–2.8)

0.91

2.0 (1.2–3.4)

0.0063

CCND1

Genotype (MT vs WT)

1.9 (1.0–3.6)

0.061

1.3 (0.8–2.1)

0.26

Immunophenotype

2.2 (1.2–4.3)

0.018

1.1 (0.6–1.9)

0.72

Stage (III–V vs I–II)

0.5 (0.3–1.1)

0.093

1.2 (0.7–1.9)

0.5

Disease status

0.9 (0.3–2.6)

0.89

2.0 (1.2–3.3)

0.0081

TP53

Genotype (MT vs WT)

1.9 (0.9–4.1)

0.12

2.7 (1.7–4.4)

<0.0001

Immunophenotype

2.5 (1.3–4.9)

0.0058

1.2 (0.7–2.0)

0.58

Stage (III–V vs I–II)

0.6 (0.3–1.2)

0.15

1.3 (0.8–2.1)

0.32

Disease status

1.1 (0.4–2.9)

0.89

1.8 (1.1–3.0)

0.022

  1. aNon-T zonal TCLs vs BCLs.
  2. bRelapsed vs naïve.
Back to article page